“RYH has 20 Bullish-rated Chaikin Power Gauge stocks vs. 4 with Bearish ratings, as indicated by the Chaikin Power Bar for the RYH below. This indicates positive potential for the RYH over the next 3 – 6 months,” according to Chaikin.

Said another way, 20 of RYH’s 55 holdings look like solid bets against just four with the potential to be laggards.

Although RYH is lighter on blue chip pharma names compared to its cap-weighted counterparts, the ETF does not short change investors when it comes to high-quality firms. The ETF is home to several companies with decades-long dividend increase streaks such as Johnson & Johnson (NYSE: JNJ) and Abbott Labs (NYSE: ABT). RYH’s pharma weight is less than 24% compared to over 44% for XLV. [Time for a Checkup With This Health Care ETF]

Guggenheim S&P Equal Weight Healthcare ETF